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Abstract
Background: GABAA receptors are members of the Cys-loop family of neurotransmitter receptors, proteins which are
responsible for fast synaptic transmission, and are the site of action of wide range of drugs [1]. Recent work has shown that
Cys-loop receptors are present on immune cells, but their physiological roles and the effects of drugs that modify their
function in the innate immune system are currently unclear [2]. We are interested in how and why anaesthetics increase
infections in intensive care patients; a serious problem as more than 50% of patients with severe sepsis will die [3–6]. As
many anaesthetics act via GABAA receptors [7], the aim of this study was to determine if these receptors are present on
immune cells, and could play a role in immunocompromising patients.
Principal Findings: We demonstrate, using RT-PCR, that monocytes express GABAA receptors constructed of a1, a4, b2, c1
and/or d subunits. Whole cell patch clamp electrophysiological studies show that GABA can activate these receptors,
resulting in the opening of a chloride-selective channel; activation is inhibited by the GABAA receptor antagonists
bicuculline and picrotoxin, but not enhanced by the positive modulator diazepam. The anaesthetic drugs propofol and
thiopental, which can act via GABAA receptors, impaired monocyte function in classic immunological chemotaxis and
phagocytosis assays, an effect reversed by bicuculline and picrotoxin.
Significance: Our results show that functional GABAA receptors are present on monocytes with properties similar to CNS
GABAA receptors. The functional data provide a possible explanation as to why chronic propofol and thiopental
administration can increase the risk of infection in critically ill patients: their action on GABAA receptors inhibits normal
monocyte behaviour. The data also suggest a potential solution: monocyte GABAA receptors are insensitive to diazepam,
thus the use of benzodiazepines as an alternative anesthetising agent may be advantageous where infection is a life
threatening problem.
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Introduction
The anaesthetic drug, propofol, is a first line agent for sedation
of critically ill patients on intensive care, facilitating potentially life-
saving invasive treatments such as mechanical ventilation [1]. Its
use, however, can have serious side effects, such as an increase in
the incidence of secondary pneumonia from 35% to 53% [2].
Thiopental is another intravenous anaesthetic used in intensive
care patients, usually for the management of patients with
refractory status epilepticus or intracranial hypertension [1], but
again can impair immune function, for example by suppressing
bone marrow haematopoiesis [3]. The extent to which these drugs
immunocompromise patients, and the contribution of this
immunological impairment to the development of septicaemia
on the intensive care unit has not been studied. However, a large
proportion of critically ill patients have a primary diagnosis of
septicaemia or severe sepsis as a result of respiratory or abdominal
infections [8], and are prone to secondary infections; risk factors
for these include blood transfusion [9], positive pressure
respiratory support [10] and intravenous nutrition [11]. The
seriousness of such infection in critically ill patients is not in doubt:
more than 50% of patients with severe sepsis will die, usually from
multiple organ failure [4]. It is known that a wide variety of
anaesthetic and analgesic drugs negatively modulate the migration
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as these drugs act at a broad range of receptors, their cytotoxic
excipients have generally been considered to be responsible [12–
14]. Recent work has shown that Cys-loop receptors are present
on immune cells, and are a potential site of drug action [15–17].
Here we consider whether propofol and thiopental act via GABAA
receptors on monocytes. These receptors are the target of a range
of anaesthetics [18] and are known to modulate T-lymphocytes in
mouse models of autoimmune diseases such as type 1 diabetes
mellitus and experimental autoimmune encephalomyelitis [19–
21]. Monocytes and macrophages produce and secrete GABA
[21,22], so the tonic paracrine inhibition of function seen in
embryonic neurons and cerebellar granule cells may play a role in
the regulation of innate immune function and inflammation. In
this report we show that GABAA receptors are expressed by
monocytes, and that action at these proteins can explain the effects
of both propofol and thiopental. The studies were performed using
freshly-prepared human monocytes whenever possible, but where
they were unsuitable we used the human myleomonocytic cell line
(THP-1), which are routinely used as a model of human monocyte
function e.g.[23].
Results
RT-PCR of RNA extracted from a human myleomonocytic cell
line (THP-1 cells) and freshly prepared human monocytes showed
that GABAA receptor subunits are expressed in these cells. In
THP-1 cells, amplimers of the correct sizes and sequences were
obtained for a4, b2, c1 and d GABAA receptor subunits (figure 1a).
In fresh monocytes, only b2 subunits could be isolated (table 1).
Expression of the b2 subunit protein was confirmed by
immunoblotting and immunohistochemistry (figure 1b). These
receptors are functional: whole cell patch clamp of THP-1 cells
showed that both GABA and the GABAA-specific agonist
muscimol elicited currents that were blocked by the GABAA
antagonists picrotoxin and bicuculline at 1 mM and 100 mM
respectively (figure 2a). The channels predominantly conducted
chloride: in whole cell patch clamp experiments the reversal
potential of the GABA-induced responses was 15.160.7 mV (all
data = mean 6 SEM, n$5), close to the theoretical value of
16.1 mV for a chloride channel, and under bi-ionic conditions was
predominantly chloride permeable (figures 2b and 2c). Due to the
small amplitudes of the whole-cell responses and the fragility of the
Figure 1. mRNA and protein expression of GABAA receptor subunits in monocytic cells. a) Typical RT-PCR of total RNA isolated from
monocyte (M) and THP-1 cell (T) lysates detecting GABAA receptor subunits. Amplimers corresponding to the expected sizes were detected for a4, c1
and d subunits of the GABAA receptor in THP-1 cells, and b2 subunits in monocytes. RNA isolated from whole human brain (B) was used as a positive
control. b) GABAA receptor b2 subunit expression in non–permeabilised human monocytes. Image of a human monocyte stained with Hoescht
33342 (left hand panel) to show the nucleus, and with a GABAA receptor b2-specific polyclonal antiserum (centre) revealing cell surface b2 subunits.
The right panel shows the merged image. Positive controls were human cerebral cortex and negative controls were neutrophils (data not shown).
Scale bar =5 mm. Data are typical of at least 6 independent experiments. Inset = typical immunoblot of a monocyte sample (left hand side) and
control (neutrophil, right hand side) probed with the b2-specific antiserum and showing expected MWt for a b2 subunit.
doi:10.1371/journal.pone.0017152.g001
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curves. However, the use of a membrane potential-sensitive dye
revealed concentration-dependent decreases in fluorescence to the
GABA-selective agonist muscimol (EC50 =2.5 mM, pEC50 =
5.6160.22, figures 2d and e), which were inhibited by the GABAA
receptor antagonists bicuculline and picrotoxin with IC50so f
135 mM (pIC50 =3.8760.29) and 29.6 mM (pIC50 =4.5360.29)
respectively. We also observed no potentiation of these effects in
the presence of the benzodiazepine diazepam, and no responses to
bicuculline and picrotoxin up to concentrations of 1 mM (data not





shown), which was consistent with the low levels of protein
expression and small currents recorded in THP-1 cells.
To examine monocyte migration we used a transwell in vitro
migration assay (figure 3). Both THP-1 cells and fresh human
monocytes migrated towards monocyte chemoattractant protein-1
(MCP-1) [24]. Propofol or thiopental inhibited this chemotaxis in
a concentration-dependent fashion; maximum inhibition was
97.360.3% for propofol and 79.063.8% for thiopental, with
IC50s of 119 mM (pIC50 =3.9360.08) and 274 mM (pIC50 =
3.5660.09) respectively. To determine if this process was
modulated via GABAA receptors, we performed the same
experiment in the presence of picrotoxin and bicuculline. Both
these compounds significantly restored migration (figure 3);
thiopental (400 mM) reduced migration to 26.962.5%, while in
the presence of bicuculline (100 mM) migration was restored to
87.066.3%. Similarly 1 mM picrotoxin increased chemotaxis
from 6.862.1% to 44.466.2% in the presence of 150 mM
propofol.
The ability of thiopental to inhibit monocyte phagocytosis of
fluorescently labelled beads was also explored to further examine
monocyte function. These data (figure 4a) demonstrated that
thiopental inhibits phagocytosis with an IC50 of 229 mM (pIC50 =
2.6460.52). This inhibition was partially prevented by application
of picrotoxin and bicuculline (figures 4b and 4c).
Discussion
The data we present here show that functional GABAA
receptors, constructed of a combination of a1, a4, b2, c1 and/
or d subunits, are present on monocytes. Whole cell patch clamp
studies show that these receptors have properties broadly similar to
CNS GABAA receptors, and the anaesthetic drugs propofol and
thiopental, which can also activate GABAA receptors, impaired
monocyte function in classic immunological chemotaxis and
phagocytosis assays. The data therefore could provide an
explanation as to why chronic propofol and thiopental adminis-
tration can increase the risk of infection in critically ill patients.
The benzodiazepine diazepam did not affect function or
modulate the effects of propofol or thiopental. Benzodiazepines
have long been known to modulate GABAA receptor responses
[25], although more recently it was shown that this capacity
critically depends on the subunit composition of the GABAA
receptors [26]. GABAA receptors are heteromeric pentamers that
most commonly contain 2a,2 b and a c subunit, although as there
are 19 GABAA receptor subunits, a large number of receptor
stoichiometries are possible. We detected a4, b2, c1 and d subunits
in THP-1 cells and b2 subunits in fresh monocytes. Detecting
RNA in the latter is problematic, due to high levels of RNAases
and difficulties in obtaining large numbers of pure monocytes, and
other subunits, such as a1, may be present. RNA for this subunit
has been previously reported in monocytes which, despite lack of
evidence of any other subunits, also responded to GABAA receptor
agonists [27]. This suggests that a likely constitution of the GABAA
receptors in monocytes is a4a1b2b2c1 and/or a4a1b2b2d,
combinations typical of tonic GABAA receptors responsible for
slower signalling in the central nervous system [28]. GABAA
receptors containing a4o rd subunits, and those lacking a c2
subunit, would be expected to be insensitive to diazepam [29]. The
detection of b2 subunits is significant, as this subunit contains a
propofol-sensitive binding site, and - intriguingly - these subunits
can assemble into functional receptors that respond to thiopental
in vitro [30,31]. Thus our RNA data are consistent with the
presence of GABAA receptors in monocytes that are not
modulated by benzodiazepines.
This first demonstration that propofol and thiopental modulate
monocyte function through actions at diazepam-insensitive
GABAA receptors has important clinical implications. If a patient’s
primary pathology is inflammatory, the immunomodulatory
effects of propofol or thiopental could be therapeutic, but if it is
infective they may increase the risk of sepsis. Recently the use of
benzodiazepines as sedatives has been largely supplanted by
propofol, but our data suggest that propofol might compromise
immune cell function, while benzodiazepines would not. This
raises the possibility that sedation strategies in critically ill patients
could be tailored to their diagnosis, with a more traditional
benzodiazepine-based approach for patients with, or at risk of,
severe sepsis.
An essential question is whether our findings are relevant in
terms of the concentrations of thiopental and propofol used in
clinical practice. Here the concentrations at which thiopental and
propofol cause a 50% reduction in monocyte chemotaxis in vitro
are 270 mM and 120 mM respectively. High dose thiopental
infusions result in a serum concentration of ,73 mg.l
21, which is
,300 mM [32], and the concentration of propofol required to
prevent 50% of patients responding to a surgical stimulus equates
Table 1. GABAA receptor subunits detected using RT-PCR in






















Typical immunoblots are show in figure 1.
doi:10.1371/journal.pone.0017152.t001
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compounds can bind to serum proteins, but this may not have
large effects at low concentrations [34] and we included serum
(bovine serum albumin) in our chemotaxis experiments to mimic
this effect. It should also be considered that whilst half maximal
effective and inhibitory (EC50 and IC50) concentrations are the
conventional means of reporting experimental data, far more
subtle reductions in function could have clinically relevant
consequences. Thus we propose that thiopental and propofol are
used in clinical practice at concentrations that have the potential to
significantly diminish monocyte function in vivo.
An immunocompromising effect of two such widely used
anaesthetics has significant consequences. Not least our data make
a strong case for investigating alternative sedation strategies for
patients depending on their primary pathology, and also add
weight to the case for developing more precise methods for
quantifying the adequacy of sedation. Clinicians titrate the doses of
sedative drugs against rather blunt endpoints, tending to err on the
side of caution (i.e. higher concentrations) to ensure that patients
are comfortable and not distressed. Recent papers have focused on
the need to minimise sedation levels in anaesthesia and critical
care to reduce complications and time spent in an intensive care
unit [35,36]. While most attention has focused on the sedative
effects of drugs in this situation, our data suggest that the increased
potential to compromise immune function may play a part. Lower
plasma concentrations or novel combinations of sedatives could
significantly improve prognoses. The same applies during surgery:
administering a larger anaesthetic dose than is necessary could
have implications for wound healing and acquisition of postoper-
ative infections.
Our findings also raise the intriguing possibility of administering
GABAA antagonists to influence immune function. Picrotoxin and
securinine have been shown to positively modulate macrophage
activity and enhance the clearance of bacteria [37,38]. A highly
charged non-toxic GABAA antagonist that does not cross the
blood brain barrier could be a means of diminishing the unwanted
peripheral effects of the agonist drugs, or might even act as a novel
non-sedating anti-inflammatory drug.
In conclusion we have demonstrated the clinical importance of
GABAA receptors on monocytes, and suggest that using
anaesthetic or sedative drugs that act via different receptors could
avoid immune impairment. At this stage it is not possible to
quantify the extent to which GABAA agonists contribute to the
acquisition of infection on the intensive care unit considering the
complex interplay of many pathophysiological processes in critical
illness and multi-organ dysfunction. Our data suggest that the
drugs used to sedate patients might be part of the problem, but
also indicate possible solutions. The hypothesis that improved or
different sedation strategies could reduce fatalities from septicae-
mia in the critically ill requires further testing, but the outcome
potentially has very great clinical implications.
Materials and Methods
Materials
All reagents were source from Sigma Aldrich (Poole, UK) unless
otherwise stated.
Cell preparation
Peripheral blood mononuclear cells were used as the source of
primary human monocytes. These had been isolated by
centrifugation of Buffy coat (Blood Transfusion Service, Cam-
bridge, UK) in Percoll gradients [39]. Monocytes were negatively
isolated using immunomagnetic beads coated with monoclonal
antibodies against human CD2, CD7, CD16, CD19, CD56 and
CD3 as previously described (Monocyte negative isolation kit;
Invitrogen, Paisley, UK) [40]. THP-1 cells (European Collection
of Cell Cultures, Salisbury, Wiltshire, UK) were maintained at a
density of between 4610
5 and 1610
6 cells/ml in RPMI 1640
supplemented with penicillin, streptomycin, 10% fetal calf serum
and 20 mM 2-mercaptoethanol.
RT-PCR
Total RNA was extracted using an RNAqueous-4PCR kit
(Ambion, Huntingdon, UK). RT-PCR reactions were prepared
using 0.2 mg of total RNA and 20 pmol oligonucleotide primers
using a SuperScript One-Step RT-PCR with Platinum Taq kit
(Invitrogen). Total RNA extracted from human brain was used for
positive controls; reactions lacking RT were also included. The
expression of the ‘housekeeping gene’ glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was also examined. The primer
sequences used to identify GABAA subunit mRNA have been
published previously [41], those for GAPDH were: ACCACA-
GTCCATGCCATCAC (sense) and TCCACCACCCTGTTG-
CTGTA (antisense). PCR conditions were: 2 min at 94uC x1;
94uC for 15 s, 55uC for 30 s and 68uC for 1 min640; 5 min at
68uC x1. Amplimers were resolved on a 1% agarose gel, extracted
and sequenced (Applied Biosystems 31306l, Applied Biosystems,
Warrington, UK). Results were compared with known mRNA
sequences on the Entrez PubMed nucleotides database (http://
www.ncbi.nlm.nih.gov/entrez) using ClustalW (http://www.ebi.
ac.uk/Tools/clustalw2).
Immunohistochemistry and immunoblotting
Cells were fixed with 4% paraformaldehyde in phosphate
buffered saline (PBS), washed in Tris buffered saline (TBS),
blocked with 3% BSA in TBS containing 0.2% Tween 20 (TTBS)
and incubated overnight in a humidified chamber at 4uC with
1:1000 b2 subunit antisera (Abcam, Cambridge, UK). After 2
washes in TTBS, the samples were incubated with FITC-
conjugated secondary antibody at room temperature for 3 h.
Following washing, the samples were dried and mounted in
Vectashield containing 49,6-diamidino-2-phenylindole (Vector,
London, UK), and examined using confocal microscopy. Immu-
noblotting was performed using standard techniques with an
overnight incubation using a 1:1000 dilution of the b2 subunit
antisera, followed by a 1 h incubation with an HRP-conjugated
secondary antibody. Bands were detected using enhanced luminol
chemiluminescent reagent (Perkin Elmer, Beaconsfield, UK).
Whole cell patch clamp
THP-1 cells were grown on fibronectin-coated sterile cover
slips. Cells were clamped at +60 mV in whole-cell configuration.
Extracellular saline consisted of (mM) 140 NaCl, 5.4 KCl, 1
MgCl2, 1.0 CaCl2, 10.0 HEPES (pH 7.2). Pipettes were filled with
Figure 2. Functional responses of GABAA receptors in THP-1 cells. a) Typical whole-cell patch-clamp traces of THP-1 cells clamped at +60 mV
in the presence of GABA and muscimol; currents were blocked by the GABAA receptor antagonists bicuculline and picrotoxin. b) Application of
muscimol (300 mM) to THP-1 cells revealed a reversal potential (Erev) of 15.1 mV, and c) chloride-selectivity (PNa/PCl) of 0.23 (n=5). d) Typical
Flexstation responses of THP-1 cells to different concentrations of muscimol. Buffer (continuous line) or muscimol (3, 10 and 100 mM, dashed lines)
were added at 20 s. e) Dose curve response of THP-1 cells; EC50 =2.5 mM, n=6.
doi:10.1371/journal.pone.0017152.g002
GABAA Receptors in Monocytes
PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e17152(mM) 140 CsCl, 1.0 MgCl2, 1.0 CaCl2, 10.0 EGTA, 10.0 HEPES
(pH 7.2). Currents were filtered at a frequency of 1 kHz (23 dB)
with a 4-pole low-pass Bessel filter and acquired at a sampling
frequency of 110 Hz. Current-voltage relationships were studied
using a voltage-ramp protocol from 280 mV to +40 mV over 1 s.
Series resistance was usually less than 5.0 MV and voltage errors
never exceeded 5 mV.
FlexStation analysis of potentiometric dyes
THP-1 cells were washed in flex buffer (in mM 115.0 NaCl, 1.0
KCl, 1.0 CaCl2, 1.0 MgCl2, 1.0 glucose, 10.0 HEPES pH 7.4) and
1610
5 cells added to each well of a 96 well plate. This was
centrifuged at 1000 rpm for 2 min to embed an even layer of cells,
and then incubated at room temperature for 45 min in 100 ml
buffer containing membrane potential dye (Blue Kit, Molecular
Figure 3. Inhibition of monocyte migration by anaesthetics is reversed by GABAA antagonists. a) Schematic representation of the in vitro
transwell chemotaxis apparatus used to assay human primary monocyte migration; b and c) Concentration-dependent inhibition of chemotaxis was
observed in the presence of propofol (PPF) and sodium thiopental (STP) (IC50s =119 mM and 274 mM, respectively, n=6); d and e) In the presence of
either propofol (PPF) or sodium thiopental (STP), chemotaxis was significantly restored by the addition of the GABAA antagonists picrotoxin (PTX) and
bicuculline (BIC); (** sig diff. Mann-Whitney U test: p,0.01). Experiments were also performed with THP-1 cells and no significant differences between
the behaviour of freshly-prepared human monocytes and THP-1 cells were seen (data not shown).
doi:10.1371/journal.pone.0017152.g003
GABAA Receptors in Monocytes
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(Molecular Devices). Fluorescence was measured every 2 s for
300 s. At 20 s, 50 ml of muscimol was added to each well. Data
was analysed using Prism (GraphPad, San Diego, USA).
Transwell filter migration assay
MCP-1 (Peprotech, London, UK) was diluted in Gey’s
Balanced Salt Solution (GBSS) with 1% BSA to a final
concentration of 12.5 ng.ml
21; 29.2 ml was added to each well
of 96 well disposable chemotaxis chamber (Neuroprobe, Gaithers-
burg, USA) and an 8 mm polycarbonate filter membrane fitted.
1610
5 monocytes in 25 ml GBSS/BSA were then placed on the
top of each well. The assembled chamber was incubated at 37uC
in a humidified atmosphere of air and 5% CO2 for 90 min.
Compounds under investigation were added in equal concentra-
tions to both the top and bottom compartments of the migration
chamber. After incubation, the cells were gently removed from the
top of the filter with a pipette, 20 ml of ice-cold 20 mM EDTA in
PBS was added to the top of each well and incubated at 4uC for
15 min. Cells that had migrated into the lower compartment of
the chamber were incubated at 37uC for 60 min with 3 ml of the
vital dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT; 5 mg/ml in RPMI-1640). The liquid was then
carefully aspirated from the wells leaving the stained cells, and the
converted formazan blue dye was solubilised using 20 ml DMSO
per well. Absorbance of the converted dye was measured at a
wavelength of 595 nm using an ELISA plate reader (Molecular
Devices). The number of cells migrated in each well was
determined by interpolation of an 8-point standard curve using
Softmax Pro (Molecular Devices).
Monocyte Phagocytosis Assay
THP-1 cells were differentiated in 200 nM phorbol 12-
myristate 13-acetate (PMA) for 24 h. Fluorescent (FITC) labelled
microspheres (Molecular Probes) were coated with 1% BSA
(2.25610
9 microspheres.ml
21) and added to the cells in 500 ml
HEPES-buffered saline (mM: 140.0 NaCl, 5.0 KCl, 2.0 CaCl2, 1.0
MgCl2, 10.0 HEPES, pH 7.4) with the compounds under
investigation and incubated for 1 h. The positive control
conditions were PMA alone; the negative control was unstimulated
THP-1 cells. The cells were then washed with ice-cold PBS
solution, fixed with 0.5% glutaraldehyde and analysed by flow
cytometry using FlowJo software (version 7.5.5, Tree Star Inc.,
OR, USA). A phagocytosis index was calculated from the average
number of beads taken up per cell.
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